Resveratrol is the compound that taught the longevity field how far a mechanism can travel without an outcome. The endothelial and inflammatory effects in randomized trials are real but small. The claim it was famous for — that it mimics caloric restriction through sirtuins — was examined directly in mice and found, on balance, to be limited in evidence and modest in size. And when resveratrol was finally put through a properly powered trial with a clinical endpoint it could plausibly hit, knee osteoarthritis pain, it performed identically to placebo.
Resveratrol (trans-3,5,4'-trihydroxystilbene) is a natural polyphenol produced by grapes, berries, peanuts and other plants as a defensive phytoalexin, and it is found in especially high concentration in red wine — though current health guidance that no level of alcohol consumption is safe has undercut the 'red wine' rationale that first popularized it. It acts as an antioxidant and has been reported to engage nutrient-sensing pathways associated with aging, including activation of SIRT1/sirtuins and AMP-activated protein kinase (AMPK). Interest in resveratrol as a longevity compound began with reports that it extended lifespan in yeast and other model organisms, though its oral bioavailability in humans is low; liposomal formulations aim to improve absorption.
Claims below are supported by the primary sources linked under each line — the same sources we cite on the product page.
Each line pairs a claim that circulates in marketing and forums with the trial result that contradicts or narrows it.
Quotations are verbatim from the cited paper. Negative and inconclusive trials are listed alongside the positive ones because that is the whole point of this page.
“At 3 months, the mean reduction in knee pain was -15.7 (95% confidence interval (CI), -21.1 to -10.3) in the resveratrol group and -15.2 (95% CI, -20.5 to -9.8) in the placebo group (absolute difference -0.6 [95% CI, -8.0 to 6.9]; p = 0.88).”
“The evidence that resveratrol acts as a caloric restriction mimetic in mammals is, on balance, limited, and the magnitude of any effect appears modest.”
Result: In most studies identified, mice supplemented with resveratrol (RSV) did not show significant reductions in body weight, glucose, or insulin. Some studies also reported that RSV and caloric restriction (CR) treatments affected molecular targets differently, and findings on their impacts varied between trials. While there might be a…
Stated limitations: The abstract notes that findings on resveratrol's effects vary between trials and that data are inconsistent, indicating a lack of clear, reproducible results across studies.
“This meta-analysis of available RCTs does not suggest any benefit of resveratrol supplementation on CV risk factors. Larger, well-designed trials are necessary to confirm these results.”
“Resveratrol supplementation did not show any significant effect on BMD or serum bone markers with the current evidence. Further investigation with more well-organized multicentre randomized trial is warranted.”
“Over 24 months, 75 mg twice-daily resveratrol improved overall cognitive performance by 33% versus placebo and enhanced cerebral blood flow and insulin sensitivity in postmenopausal women — a single-cohort result awaiting replication.”
In human health, the best-supported effects of resveratrol come from randomized trials and meta-analyses in people with metabolic or cardiovascular risk: pooled trials show modestly better endothelial function (flow-mediated dilation) and small reductions in C-reactive protein, especially at 500 mg/day or more for 10 weeks or longer, alongside improved glucose control in diabetes, while blood-pressure effects are inconsistent overall. A 24-month trial in postmenopausal women reported better cognition, cerebral blood flow and insulin sensitivity, but that finding comes largely from one research group and awaits independent replication, and an umbrella review of the trial literature rates much of the evidence as low certainty. No trial has shown effects on hard outcomes such as cardiovascular events, dementia or lifespan; the celebrated sirtuin longevity mechanism remains preclinical, effects in healthy young adults and on bone density were null, and the superiority of liposomal delivery is unproven in humans. This evidence describes the compound trans-resveratrol and its mechanisms, not this specific commercial liposomal product.
A grade that cannot be falsified is a marketing claim. These are the specific results that would move this one up.
If the reason you want resveratrol is vascular — flow-mediated dilatation, CRP — the meta-analytic signal is real, modest, and appears at 500 mg/day or more for at least 10 weeks. Buy on price and third-party testing rather than on formulation claims. If the reason is longevity, sirtuins or red wine, the honest answer is that the evidence for that story has been tested and has not held up, and your money buys more elsewhere.
Graded Strong. If you want an ingestible with consistent randomized human evidence behind it, this is the one in this catalogue.
Graded Strong. Vascular health is the one thing resveratrol plausibly touches — blood pressure is the version of it you can actually measure and act on.
The other NAD+/sirtuin-adjacent compound where a biomarker effect has been marketed as an aging effect.
Dose, trans- versus cis-, bioavailability and third-party testing, if you are buying anyway.
Resveratrol molecule page · Pterostilbene · NAD+ pathway · NMN, resveratrol and pterostilbene stacks · The caloric-restriction mimetic review, in full · The graded supplement guide
Sibling pages in this record: NMN (nicotinamide mononucleotide) · Vitamin D · Omega-3 fish oil · Blue-light filtering glasses
Open Purovitalis Liposomal Trans-Resveratrol in the Magellan store →
No — and that is exactly the distinction this page is trying to hold. Randomized trials show small improvements in endothelial function and C-reactive protein, and a long trial in postmenopausal women showed cognitive and cerebrovascular benefit. What has not survived testing is the specific story that made resveratrol famous: sirtuin activation as caloric-restriction mimicry, producing longer life.
ARTHROL randomized adults with knee osteoarthritis to oral resveratrol or placebo. At three months, pain had fallen 15.7 points in the resveratrol arm and 15.2 points in the placebo arm — an absolute difference of −0.6 with a p-value of 0.88. Both arms improved, which is what placebo-controlled trials in pain usually show, and the drug added nothing.
Not a useful comparison. Trials showing effects use doses in the hundreds of milligrams per day; the trans-resveratrol content of wine is orders of magnitude lower. The red-wine framing is a story about where the molecule was found, not about a dose anyone has tested.
Because the endothelial and CRP meta-analyses are real randomized evidence, and Moderate is our label for several human studies pointing the same way with limits on size, duration, funding or consistency. Moderate is not an endorsement of the longevity claim — the grade note on the product page says the sirtuin longevity mechanism remains preclinical.